SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
NCT ID: NCT00844285
Last Updated: 2023-05-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3072 participants
OBSERVATIONAL
2009-01-30
2020-08-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
NCT00552344
Optimizing Cimzia in Crohn's Patients
NCT01024647
Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease
NCT01817972
Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab
NCT00308581
EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment
NCT01582568
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cimzia Cohort:
Patients about to receive treatment with Cimzia® as part of pre-existing management plan for Crohn's disease or has already been receiving treatment with Cimzia® for ≤12 months. Patients must also receive a Cimzia dose within 2 months following enrollment.
Cimzia
The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.
Comparison cohort
Patient must be about to receive treatment with any other medication as part of a pre-existing management plan for Crohn's disease or has already been receiving treatment (previous Cimzia® treatment is prohibited).
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cimzia
The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The decision to prescribe Cimzia or other medications has been made by the physician independent of inclusion in this study
* Patient (or his/her legally acceptable representative) is able to provide written informed consent to permit collection of data
* Patients participating in randomized, blinded clinical trials for CD or other conditions are not eligible for inclusion into the SECURE registry. Involvement in other registries, where patients follow routine clinical practice, is permitted, however
* For the Cimzia cohort: Patient is receiving treatment with Cimzia for the first time. Patient must receive Cimzia treatment within 2 months of enrollment into the registry
* Patient is currently receiving treatment with Cimzia for \<=12 months. Patient must also receive a Cimzia dose within 2 months following enrollment into the registry
* For the comparison cohort: Patient is switching CD treatment or beginning CD treatment for the first time. Previous Cimzia treatment is prohibited in the comparator group. Patient must receive new CD treatment within 2 months of enrollment into the registry. Patient is currently receiving anti-TNF treatment for \<=12 months. Patient must receive anti-TNF treatment within 2 months following enrollment into the registry. Patient is currently receiving immunosuppressant therapy for \<=12 months. Patient must receive immunosuppressant therapy within 2 months following enrollment into the registry. Patient is currently receiving systemic steroid therapy for \<=12 months. Patient must receive systemic steroid therapy within 2 months following enrollment into registry.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB BIOSCIENCES, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Cares
Role: STUDY_DIRECTOR
001 844 599 2273(UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
C87075 931
Birmingham, Alabama, United States
C87075 198
Birmingham, Alabama, United States
C87075 286
Huntsville, Alabama, United States
C87075 032
Montgomery, Alabama, United States
C87075 253
Scottsdale, Arizona, United States
C87075 307
Tucson, Arizona, United States
C87075 377
Tucson, Arizona, United States
C87075 574
North Little Rock, Arkansas, United States
C87075 059
Beverly Hills, California, United States
C87075 580
Encino, California, United States
C87075 021
Fountain Valley, California, United States
C87075 261
La Jolla, California, United States
C87075 220
Los Angeles, California, United States
C87075 728
Oceanside, California, United States
C87075 571
Palm Springs, California, United States
C87075 485
San Carlos, California, United States
C87075 027
Torrance, California, United States
C87075 946
Boulder, Colorado, United States
C87075 491
Lonetree, Colorado, United States
C87075 087
Hamden, Connecticut, United States
C87075 077
Hartford, Connecticut, United States
C87075 097
Torrington, Connecticut, United States
C87075 639
Altamonte Springs, Florida, United States
C87075 049
Boca Raton, Florida, United States
C87075 871
Boca Raton, Florida, United States
C87075 002
Gainesville, Florida, United States
C87075 759
Hialeah, Florida, United States
C87075 893
Hollywood, Florida, United States
C87075 143
Lakeland, Florida, United States
C87075 970
Largo, Florida, United States
C87075 030
Lauderdale Lakes, Florida, United States
C87075 009
Maitland, Florida, United States
C87075 003
Miami, Florida, United States
C87075 004
Miami, Florida, United States
C87075 102
Miami, Florida, United States
C87075 420
Miami, Florida, United States
C87075 034
Naples, Florida, United States
C87075 031
Orlando, Florida, United States
C87075 487
Orlando, Florida, United States
C87075 935
Orlando, Florida, United States
C87075 074
Palm Coast, Florida, United States
C87075 183
Sarasota, Florida, United States
C87075 144
Tampa, Florida, United States
C87075 046
Titusville, Florida, United States
C87075 271
Vero Beach, Florida, United States
C87075 280
Weston, Florida, United States
C87075 729
Winter Park, Florida, United States
C87075 399
Atlanta, Georgia, United States
C87075 288
Atlanta, Georgia, United States
C87075 849
Atlanta, Georgia, United States
C87075 232
Covington, Georgia, United States
C87075 357
Cumming, Georgia, United States
C87075 336
Decatur, Georgia, United States
C87075 113
Decatur, Georgia, United States
C87075 988
Decatur, Georgia, United States
C87075 698
Johns Creek, Georgia, United States
C87075 083
Lawrenceville, Georgia, United States
C87075 067
Macon, Georgia, United States
C87075 897
Macon, Georgia, United States
C87075 488
Marietta, Georgia, United States
C87075 229
Boise, Idaho, United States
C87075 245
Idaho Falls, Idaho, United States
C87075 037
Meridian, Idaho, United States
C87075 278
Arlington Heights, Illinois, United States
C87075 418
Chicago, Illinois, United States
C87075 168
Chicago, Illinois, United States
C87075 858
Evanston, Illinois, United States
C87075 208
Hoffman Estates, Illinois, United States
C87075 368
Oak Lawn, Illinois, United States
C87075 370
Oakbrook Terrace, Illinois, United States
C87075 151
Indianapolis, Indiana, United States
C87075 124
Indianapolis, Indiana, United States
C87075 343
Clive, Iowa, United States
C87075 204
Lexington, Kentucky, United States
C87075 072
Baton Rouge, Louisiana, United States
C87075 214
Hammond, Louisiana, United States
C87075 108
Metairie, Louisiana, United States
C87075 997
New Orleans, Louisiana, United States
C87075 987
Shreveport, Louisiana, United States
C87075 235
Annapolis, Maryland, United States
C87075 040
Annapolis, Maryland, United States
C87075 181
Baltimore, Maryland, United States
C87075 953
Baltimore, Maryland, United States
C87075 591
Towson, Maryland, United States
C87075 091
Boston, Massachusetts, United States
C87075 567
Boston, Massachusetts, United States
C87075 395
Newton, Massachusetts, United States
C87075 939
North Adams, Massachusetts, United States
C87075 869
Ann Arbor, Michigan, United States
C87075 260
Chesterfield, Michigan, United States
C87075 195
Kalamazoo, Michigan, United States
C87075 349
Novi, Michigan, United States
C87075 579
Troy, Michigan, United States
C87075 373
Wyandotte, Michigan, United States
C87075 167
Wyoming, Michigan, United States
C87075 843
Wyoming, Michigan, United States
C87075 829
Ypsilanti, Michigan, United States
C87075 215
Plymouth, Minnesota, United States
C87075 501
Rochester, Minnesota, United States
C87075 867
Ocean Springs, Mississippi, United States
C87075 540
Bridgeton, Missouri, United States
C87075 163
Columbia, Missouri, United States
C87075 776
Lee's Summit, Missouri, United States
C87075 305
Mexico, Missouri, United States
C87075 085
St Louis, Missouri, United States
C87075 835
St Louis, Missouri, United States
C87075 937
Las Vegas, Nevada, United States
C87075 740
Lebanon, New Hampshire, United States
C87075 323
Nashua, New Hampshire, United States
C87075 005
Cherry Hill, New Jersey, United States
C87075 705
Egg Harbor, New Jersey, United States
C87075 930
Marlton, New Jersey, United States
C87075 610
Mays Landing, New Jersey, United States
C87075 161
Ridgewood, New Jersey, United States
C87075 165
Woodbury, New Jersey, United States
C87075 024
Brooklyn, New York, United States
C87075 362
Flushing, New York, United States
C87075 413
Great Neck, New York, United States
C87075 517
Great Neck, New York, United States
C87075 321
Jericho, New York, United States
C87075 541
Lake Success, New York, United States
C87075 118
New York, New York, United States
C87075 712
New York, New York, United States
C87075 494
New York, New York, United States
C87075 018
New York, New York, United States
C87075 159
Poughkeepsie, New York, United States
C87075 300
Rochester, New York, United States
C87075 884
Stony Brook, New York, United States
C87075 051
Asheville, North Carolina, United States
C87075 636
Chapel Hill, North Carolina, United States
C87075 185
Charlotte, North Carolina, United States
C87075 965
Charlotte, North Carolina, United States
C87075 945
Concord, North Carolina, United States
C87075 973
Fayetteville, North Carolina, United States
C87075 527
Greenville, North Carolina, United States
C87075 127
Kinston, North Carolina, United States
C87075 926
New Bern, North Carolina, United States
C87075 779
Rocky Mount, North Carolina, United States
C87075 932
Wilmington, North Carolina, United States
C87075 955
Bismarck, North Dakota, United States
C87075 239
Canton, Ohio, United States
C87075 807
Canton, Ohio, United States
C87075 042
Cincinnati, Ohio, United States
C87075 016
Cincinnati, Ohio, United States
C87075 462
Cleveland, Ohio, United States
C87075 314
Lima, Ohio, United States
C87075 929
Mentor, Ohio, United States
C87075 777
Tulsa, Oklahoma, United States
C87075 172
Tulsa, Oklahoma, United States
C87075 213
Portland, Oregon, United States
C87075 947
Allentown, Pennsylvania, United States
C87075 241
Hermitage, Pennsylvania, United States
C87075 460
Malvern, Pennsylvania, United States
C87075 166
Philadelphia, Pennsylvania, United States
C87075 086
Pittsburgh, Pennsylvania, United States
C87075 176
Charleston, South Carolina, United States
C87075 813
Columbia, South Carolina, United States
C87075 922
Sioux Falls, South Dakota, United States
C87075 299
Franklin, Tennessee, United States
C87075 262
Hermitage, Tennessee, United States
C87075 757
Jackson, Tennessee, United States
C87075 224
Knoxville, Tennessee, United States
C87075 390
Nashville, Tennessee, United States
C87075 894
Nashville, Tennessee, United States
C87075 596
Union City, Tennessee, United States
C87075 272
Austin, Texas, United States
C87075 200
Austin, Texas, United States
C87075 941
Dallas, Texas, United States
C87075 628
Dallas, Texas, United States
C87075 088
Fort Sam Houston, Texas, United States
C87075 226
Fort Worth, Texas, United States
C87075 237
Houston, Texas, United States
C87075 419
Houston, Texas, United States
C87075 726
Houston, Texas, United States
C87075 312
Pasadena, Texas, United States
C87075 657
San Antonio, Texas, United States
C87075 923
San Antonio, Texas, United States
C87075 279
Southlake, Texas, United States
C87075 366
Temple, Texas, United States
C87075 539
Tyler, Texas, United States
C87075 986
Salt Lake City, Utah, United States
C87075 814
Burlington, Vermont, United States
C87075 963
Colchester, Vermont, United States
C87075 675
Christiansburg, Virginia, United States
C87075 691
Norfolk, Virginia, United States
C87075 446
Richmond, Virginia, United States
C87075 026
Virginia Beach, Virginia, United States
C87075 273
Woodbridge, Virginia, United States
C87075 471
Seattle, Washington, United States
C87075 925
Tacoma, Washington, United States
C87075 465
Green Bay, Wisconsin, United States
C87075 116
Madison, Wisconsin, United States
C87075 070
Milwaukee, Wisconsin, United States
C87075 281
Milwaukee, Wisconsin, United States
C87075 389
Milwaukee, Wisconsin, United States
C87075 578
Milwaukee, Wisconsin, United States
C87075 093
Oshkosh, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lichtenstein GR, Lee SD, Feagan BG, Loftus EV Jr, Ng S, Dehlin K, Quinn P, Coarse J, Rosario-Jansen T, Arendt C, Stark JL. Certolizumab Pegol Treatment in Patients With Crohn's Disease: Final Safety Data From the SECURE Registry. Crohns Colitis 360. 2025 Jan 25;7(1):otae083. doi: 10.1093/crocol/otae083. eCollection 2025 Jan.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C87075
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.